Stock News

Arqule Inc (NASDAQ:ARQL) Stock Is Shorted Less

ArQule, Inc. (NASDAQ:ARQL) Logo

The stock of Arqule Inc (NASDAQ:ARQL) registered a decrease of 7.62% in short interest. ARQL’s total short interest was 5.64M shares in November as published by FINRA. Its down 7.62% from 6.10 million shares, reported previously. With 1.17 million shares average volume, it will take short sellers 5 days to cover their ARQL’s short positions.

The stock decreased 1.72% or $0.07 during the last trading session, reaching $3.99. About 805,899 shares traded. ArQule, Inc. (NASDAQ:ARQL) has risen 397.32% since November 10, 2017 and is uptrending. It has outperformed by 381.70% the S&P500.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company has market cap of $434.89 million. The Company’s lead product candidate is tivantinib , a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. It currently has negative earnings. The companyÂ’s clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death.

ArQule, Inc. (NASDAQ:ARQL) Ratings Coverage

Among 2 analysts covering Arqule (NASDAQ:ARQL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Arqule has $7.5 highest and $700 lowest target. $7.25’s average target is 81.70% above currents $3.99 stock price. Arqule had 2 analyst reports since June 11, 2018 according to SRatingsIntel. The stock has “Buy” rating by FBR Capital on Friday, June 29. The firm earned “Buy” rating on Monday, June 11 by Oppenheimer.

More recent ArQule, Inc. (NASDAQ:ARQL) news were published by: Businesswire.com which released: “ArQule to Present Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium” on November 08, 2018. Also Seekingalpha.com published the news titled: “ArQule up 5% on encouraging miransertib data” on October 18, 2018. Nasdaq.com‘s news article titled: “New Research Coverage Highlights TIER REIT, Meridian Bioscience, ArQule, Greenlight Capital Re, ADT, and …” with publication date: October 19, 2018 was also an interesting one.

ArQule, Inc. (NASDAQ:ARQL) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*